Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) (N-Term) Peptide
IRAK4
Reactivity: Human
Host: Synthetic
BP, WB
-
- Target See all IRAK4 products
- IRAK4 (Interleukin-1 Receptor-Associated Kinase 4 (IRAK4))
- Protein Region
- N-Term
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Sequence
- VQQKQMPFCD KDRTLMTPVQ NLEQSYMPPD SSSPENKSLE VSDTRFHSFS
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-IRAK4 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- IRAK4 (Interleukin-1 Receptor-Associated Kinase 4 (IRAK4))
- Synonyms
- zgc:55553 Peptide, IRAK4 Peptide, ipd1 Peptide, irak-4 Peptide, ny-ran-64 Peptide, ny-ren-64 Peptide, ren64 Peptide, irak4 Peptide, IPD1 Peptide, IRAK-4 Peptide, NY-REN-64 Peptide, REN64 Peptide, 8430405M07Rik Peptide, 9330209D03Rik Peptide, interleukin 1 receptor associated kinase 4 Peptide, interleukin-1 receptor-associated kinase 4 Peptide, IRAK4 Peptide, irak4 Peptide, Irak4 Peptide
- Background
-
This gene encodes a kinase that activates NF-kappaB in both the Toll-like receptor (TLR) and T-cell receptor (TCR) signaling pathways. The protein is essential for most innate immune responses. Mutations in this gene result in IRAK4 deficiency and recurrent invasive pneumococcal disease. Multiple transcript variants encoding different isoforms have been found for this gene.
Alias Symbols: IRAK4,
Protein Size: 460 - Gene ID
- 51135
- UniProt
- Q9NWZ3
-
You are here:
